Eli Lilly and Co
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
Trial Comparing 3 and 4 Week Regimen of Gemcitabine and Cisplatin in Patients With Lung Cancer
- Conditions
- Non-Small Cell Lung Cancer
- First Posted Date
- 2007-06-22
- Last Posted Date
- 2007-06-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 100
- Registration Number
- NCT00489996
- Locations
- 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shanghai, China
Trial of Pemetrexed or Pemetrexed With Gemcitabine for Patients With Advanced Lung Cancer Who Are Not Eligible for Platinum-Based Chemotherapy and Have Not Previously Been Treated With Chemotherapy
- Conditions
- Non-Small Cell Lung Cancer
- First Posted Date
- 2007-06-22
- Last Posted Date
- 2007-06-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 91
- Registration Number
- NCT00489983
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, United Kingdom
A Study of LY573636-Sodium in the Treatment of Patients With Metastatic Soft Tissue Sarcoma
- Conditions
- Sarcoma, Soft Tissue
- Interventions
- Drug: LY573636-sodium
- First Posted Date
- 2007-06-22
- Last Posted Date
- 2019-09-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 101
- Registration Number
- NCT00490451
- Locations
- 🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain
Duloxetine Versus Placebo for Fibromyalgia
- Conditions
- Fibromyalgia
- First Posted Date
- 2007-06-21
- Last Posted Date
- 2007-06-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 345
- Registration Number
- NCT00489073
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Indianapolis, Indiana, United States
Trial of Pemetrexed and Carboplatin in Patients With Recurrent Ovarian or Primary Peritoneal Cancer
- Conditions
- Ovarian CancerPrimary Peritoneal Cancer
- Interventions
- First Posted Date
- 2007-06-21
- Last Posted Date
- 2011-06-16
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 86
- Registration Number
- NCT00489359
- Locations
- 🇸🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lund, Sweden
Duloxetine Versus Paroxetine for Major Depression
- Conditions
- Major Depressive Disorder
- First Posted Date
- 2007-06-21
- Last Posted Date
- 2007-06-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 480
- Registration Number
- NCT00489775
- Locations
- 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Beijing, China
Comparison of Two Basal Insulin Therapies for Patients With Type 1 Diabetes
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Drug: Insulin LevemirDrug: Insulin Lispro Protamine Suspension
- First Posted Date
- 2007-06-18
- Last Posted Date
- 2010-11-04
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 387
- Registration Number
- NCT00487240
- Locations
- 🇷🇺
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint Petersburg, Russian Federation
Olanzapine Versus Comparator in the Treatment of Bipolar Disorder
- Conditions
- Bipolar Disorder
- First Posted Date
- 2007-06-13
- Last Posted Date
- 2007-06-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 140
- Registration Number
- NCT00485680
- Locations
- 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shanghai, China
Evaluation of Continuous Symptom Treatment of ADHD
- Conditions
- Attention Deficit Hyperactivity Disorder
- First Posted Date
- 2007-06-13
- Last Posted Date
- 2007-06-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 282
- Registration Number
- NCT00486122
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Columbus, Ohio, United States
Combination Therapy in Patients With Depression
- Conditions
- Depressive Symptoms
- First Posted Date
- 2007-06-13
- Last Posted Date
- 2007-06-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 214
- Registration Number
- NCT00485862
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559), Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seattle, Washington, United States